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doi:10.1016/j.ejvs.2010.02.024Abstract Background: For reasons that are poorly understood, there appear to be differ-
ences in the prevalence of chronic venous insufficiency (CVI) and venous thromboembolism
between Caucasians and Asians.
Objectives: To compare levels of procoagulant factors and homocysteine (Hcy) in Hong Kong
(HK) Chinese and United Kingdom (UK) Caucasian populations of patients with CVI (patients
of CEAP clinical stages C4 e C6).
Methods: HK Chinese and UK Caucasian patients with CEAP clinical grade 4e6 venous disease
were enrolled. Patients with conditions known to be associated with thrombophilia (TP) were
excluded. UK and HK patients were matched by gender, age (within 5 years) and by CEAP clin-
ical grade. All subjects underwent clinical examination, venous duplex ultrasound, and
measurement of Hcy and factors (F) VIII, IX and XI.
Results: 63 Patients were enrolled in each group: Mean age 64y (HK group); 67y (UK group).
37% were female; 19% had active venous ulceration. One-third of patients in each group had
deep venous reflux. High Hcy, FIX and FXI were significantly more common in the UK group.
Multiple TP was more common in the UK group: raised levels of 2 factors in 26 vs. 14 patients
(P Z 0.022, c2). Median Hcy (14.3 vs. 10.8 mmol/L; P < 0.0005, Wilcoxon signed rank [WSR]),
FIX (131 vs. 115%; PZ 0.048), and FXI (114 vs. 97%; PZ 0.002) were significantly higher in the
UK group. There was no significant difference in FVIII levels.m University Department of Vascular Surgery, Flat 5 Netherwood House, Solihull Hospital, Lode Lane,
el./fax: þ44 121 424 5086.
rnet.com (K.A.L. Darvall).
ty for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Known blood clotting disorders
Previous venous thromboembolism
Previous superficial thrombophleb
Previous/current anticoagulant us
History of malignancy
Symptomatic arterial disease þ/
pressure index 0.9 if pedal pu
Symptomatic ischaemic heart dise
previous cardiac surgery or angi
Connective tissue disorders, inclu
Any other known acute or chronic
3 months
Inflammatory bowel disease
Surgery 3 months
Orthopaedic surgery/fracture 6
Pregnancy e current or 6 month
Hypothyroidism or hyperthyroidism
Known hepatic or renal insufficienConclusions: Raised procoagulant factors were more common in Caucasians compared with
Chinese patients with CVI in this study. As with the inherited thrombophilias, the pattern of
raised procoagulant factors in Chinese patients appears to differ from that in Caucasians.
ª 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
For poorly understood genetic and environmental reasons,
there appear to be significant differences in the prevalence of
chronic venous insufficiency (CVI) between Caucasians and
Asians. Lower limb deep vein thrombosis (DVT), one of the
principal causes of CVI, appears to be much less common in
Asians than in Caucasians.1,2 This difference may be, at least
in part, because the most important genetically determined
risk factors for DVT in Caucasians, namely the factor V Leiden
(FVL) andprothrombin (PT) geneG20210Amutations, are very
rare in Asians,3e8 and because Caucasians, especially those
with CVI, have higher levels of homocysteine (Hcy) and
coagulation factors (FVIII, FIX and FXI).9,10
The aim of the present study was to compare United
Kingdom (UK) Caucasian and Hong Kong (HK) Chinese pop-
ulations of patients with CVI in terms of homocysteine (Hcy)
and coagulation factor levels.
Methods
Following ethics approval and obtaining informed written
consent from all volunteers, HK Chinese and UK Caucasian
CVI (CEAP clinical grade 4e6)11 patients who did not have
a condition known to be associated with an acquired
thrombophilic defect (Table 1) were recruited at Kwong
Wah Hospital, Hong Kong, Peoples Republic of China (PRC)
and Heart of England NHS Foundation Trust, Birmingham,
UK, respectively. These were consecutive patients seen in
outpatient clinics at both hospitals. UK and HK patients
were matched by gender, age (within 5 years), and by CEAP
clinical grade (C4 and C5 were combined) on a one-to-one
basis.itis
e
ankle-brachial
lses impalpable
ase (e.g., angina,
oplasty)
ding rheumatoid arthritis
inflammatory process
months
s
cyIn all patients both lower limbs were examined for
evidence of venous disease, and each graded according to the
CEAP clinical (C) grade.11 All patients underwent duplex
ultrasound examination of both lower limbs conducted by one
of the authors (RS). Each scan was conducted to a standard
protocol, with the subject supported in the upright position
and the examined leg non-weight-bearing and slightly flexed
at the knee. Both the deep and superficial veinswere assessed
for patency and presence of reverse flow. The calf veins were
not assessed. Reflux was induced by manual calf augmenta-
tion, and significant reflux was defined as >0.5 s reverse flow
on the Doppler spectrum. All subjects had palpable pedal
pulses and/or an ankle-brachial pressure index >0.9.
At both sites a non-fasting sample of venous blood drawn
from an antecubital fossa vein was immediately centrifuged
at 2000 g for 15 min at room temperature. Hcy samples
were centrifuged at 4 C to prevent cells continuing to
produce Hcy in the tube.12 Serum and plasma were stored
at 80 C until assayed as a single batch in the Heart of
England NHS Trust accredited laboratories under the
supervision of one of the authors (CF). Total plasma Hcy
concentration was determined using high-pressure liquid
chromatography (DS30; Drew, Cumbria, England) as previ-
ously described.12 Factors VIII, IX and XI activities (%, where
100% is equal to 100 IU/dl) were measured on a fully-
automated coagulation analyzer using standard reagents
(MDA II, Biomerieux, Basingstoke, Hampshire, UK) by a one-
step clotting assay using clotting factor-deficient plasma.
Hyperhomocysteinaemia was defined as a total plasma Hcy
level above 15 mmol/L (95th percentile of the general
Caucasian population).13,14 Elevated factor activities were
defined as FVIII > 150%, FIX > 129% and FXI > 121% (90th
percentile values of the control Caucasian population in
published studies).15e17 There is no published evidence that
Hcy and clotting factor levels in the general Asian pop-
ulation differ from the general Caucasian population, and
indeed the published studies on thrombophilia in Asian
populations use similar reference ranges.18e23
A sample size calculation indicated that up to 27 patients
would be required in each group to detect a difference of at
least 30% in the activities of factors VIII, IX and XI, and of
4 mmol/L in plasma Hcy levels, with two-tailed 5% signifi-
cance level and a power of 80% (specific sample sizes
required were 27, 23, 19 and 17 for factors VIII, IX and XI and
homocysteine respectively). Wilcoxon signed ranks test and
Chi-squared test were used to determine differences
between the UK and HK groups. The Statistical Package for
the Social Sciences (SPSS), version 17.0 software (SPSS, Chi-
cago, IL, USA) was used for data analysis.Results
There were 63 HK Chinese patients and 63 UK Caucasian
patients enrolled in the study. The characteristics and basic
Figure 1 The percentage of patients with a high level of each
procoagulant factor. (P values obtained from chi-squared test).
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Table 2. One-third of patients in each group had deep
venous reflux, but none had evidence of post-thrombotic
deep vein damage on duplex ultrasound scan.
The percentage of patients with abnormally high levels
of each procoagulant factor according to published refer-
ence ranges (detailed above) were calculated for both
groups. Fig. 1 shows that raised levels of each procoagulant
factor were much more common in the UK group compared
with the HK group: 41% of the UK group had Hcy levels
>15 mmol/L compared with 9% of the HK group (PZ 0.0001,
c2); FVIII levels were raised (>150% activity) in 19% of the
UK group and 14% of the HK group (PZ 0.47, c2); raised FIX
levels (>129% activity) were found in 52% of the UK group
and 32% of the HK group (P Z 0.029, c2); and FXI levels
were raised (>121% activity) in 40% of the UK group and 19%
of the HK group (P Z 0.011, c2).
Using the same published reference ranges Fig. 2 shows
the number of patients with raised levels of no, one, or two
or more of the four factors studied. Multiple TP was also
more common in the UK group, with 26 of the patients
having raised levels of two or more of the four factors
studied, compared with 14 of the HK group (PZ 0.022, c2).
Hcy levels were significantly higher in the UK group
(median 14.3 mmol/L; interquartile range [IQR] 11.2e16.0)
than the HK group (median 10.8 mmol/L; IQR 8.9e13.1;
P < 0.0005, Wilcoxon signed ranks test) (Fig. 3). FVIII
activity showed no significant difference between the
groups (Fig. 4). FIX activity was significantly higher in the
UK group (median 131%; IQR 114-143) than the HK group
(median 115%; IQR 103-131; P Z 0.048) (Fig. 5). Factor XI
activity was also significantly higher in the UK group
(median 114%; IQR 91-135) compared with the HK group
(median 97%; IQR 83-116; P Z 0.002) (Fig. 6).Table 2 Demographic data and basic CEAP classification.a
Age:
Mean (range) in yrs
Gender:
Female
CEAP clinical grade of worst limb:
C4
C5
C6
Etiology:
Primary (EP)
Secondary (ES)
Anatomical patterns of venous reflux:
Superficial only (AS)
Deep only (AD)
Both superficial and deep (ASD)
Pathophysiological classification:
Reflux (PR)
Obstruction (PO)
a Values in table are numbers with percentages in brackets unless oDiscussion
The main findings of this study are that levels of the pro-
coagulants FIX and FXI and of Hcy are significantly higher in
the Caucasian (UK) population with CVI compared with an
age and sex-matched Hong Kong Chinese population also
with CVI.
Venous thromboembolism (VTE) has been traditionally
found to be less common in Asian populations than in
Caucasians, although recent data suggest that the preva-
lence is increasing.5,24e26 Studies comparing the risk factors
for VTE have consistently found differences between
Caucasian and Asian populations in the genetic determi-
nants of VTE. While the mutations FVL and PT20210A
account for a large number of VTE cases in Caucasians,3,4
these mutations are rarely found in Asians.5e8 Conversely,
the prevalence of deficiencies of the naturally occurring
coagulation inhibitors, protein C, protein S and anti-
thrombin III are higher in the general Thai, Chinese and
Japanese populations compared with Caucasians.5,7,8,24Hong Kong
Chinese
United Kingdom
Caucasian
64 (34e87) 67 (31e84)
23 (37) 23 (37)
27 (43) 26 (41)
24 (38) 25 (40)
12 (19) 12 (19)
63 (100) 63 (100)
0 (0) 0 (0)
40 (64) 42 (67)
4 (6) 7 (11)
19 (30) 14 (22)
63 (100) 63 (100)
0 (0) 0 (0)
therwise stated.
Figure 2 The prevalence of multiple raised procoagulant
factors in Hong Kong Chinese patients and UK Caucasian
patients with chronic venous insufficiency. Chi-squared: HK
2 þ TP vs. UK 2 þ TP, P Z 0.022. TP, thrombophilia.
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to be very different to Caucasians.
More recently, a number of acquired procoagulant
thrombophilic defects, have been found to be associated
with an increased risk of VTE in Caucasians. Previously
published work from our group supports the hypothesis that
patients with raised levels of procoagulants may beFigure 3 Box and whisker plot indicating total homocysteine
levels for UK Caucasian vs. HK Chinese patients. The horizontal
line inside each box indicates the median; the box itself
represents the interquartile range (IQR). Dots represent
outliers which are observations lying more than 1.5 times the
IQR from the first or third quartile. Asterisks represent
extremes which are values more than 3 times the IQR above or
below the third or first quartile respectively. Whiskers repre-
sent the largest and smallest values that are not outliers or
extremes. P value from Wilcoxon signed ranks test.predisposed to thrombosis on both a macrovascular and
microvascular level which may contribute to the skin
changes of CVI. Specifically, we found significantly higher
levels of FVIII, FIX, FXI and Hcy when compared with age
and sex-matched controls with no clinical or duplex
evidence of venous disease.10 The aim of the current study
was to determine whether these acquired procoagulants
are also raised in Chinese patients with CVI.Homocysteine
Hyperhomocysteinaemia (HHcy) has been associated with
both arterial and venous thrombosis and is often defined as
a level >15 mmol/L,13 a value determined from the 95th
percentile of the general Caucasian population. It is
believed that an increase of 5 mmol/L is associated with
a 2e3-fold increase in VTE risk.14,27e29 A meta-analysis
found the prevalence of HHcy in Caucasian VTE patients
ranged from 5.7 to 34.8% and in healthy controls from 0.0 to
7.1%.14 The pooled odds ratio (OR) for VTE in the presence
of HHcy was 2.95.14 In studies of healthy Chinese pop-
ulations HHcy has been found to have a similar, if not
higher, prevalence to that seen in Caucasian healthy pop-
ulations. Gao et al. found HHcy in 44% of men (mean level
12.6 mmol/L) and 22% of women (mean level 8.4 mmol/L)
with a mean age of 42 years, in an urban population in
Beijing, China.20 However, their definition of HHcy was
much lower than in other published studies (>12 mmol/L for
men, and >11 mmol/L for women). Their mean Hcy values
were however similar to another study of Hcy in an urban
Chinese population; mean Hcy 15.4 mmol/L in men of 35e64
years and 12.2 mmol/L in women aged 35e64 years.21 Their
prevalence rate of HHcy was 15.3%. The Singapore Chinese
Health Study found mean Hcy levels of 11.2 mmol/L in men
(mean age 58 years) and 9.1 mmol/L in women (mean age 57
years) with 95th percentile values of 17.4 and 16.5 mmol/L
respectively.22
Two published studies have looked at HHcy as a risk
factor for VTE in Asian patients. The first, a case-control
study of Taiwanese Chinese individuals with VTE and normal
controls found neither plasma Hcy level (OR 1.07) or HHcy
(>15 mmol/L; OR 1.65) were significantly associated with
VTE.23 Mean Hcy level in the cases was 10.5 mmol/L and
8.9% had HHcy (mean age 51 years). HHcy was also not
associated with recurrent VTE in this study. The second
study was a series of 105 consecutive Thai patients with
VTE.19 Of the 85 patients in the series without malignancy
(mean age 43 years), only 5.3% had HHcy (defined as
>15 mmol/L). Apart from two previous studies from our
group which found HHcy to be prevalent in Caucasian
patients with CVI (up to 65% in patients with active ulcer-
ation) there are no published studies looking at Hcy,10,12 or
indeed factors VIII, IX or XI, and CVI. In this study we found
that total homocysteine levels were significantly lower in
the Chinese patients compared with the Caucasian controls
and HHcy was significantly less common in Chinese than
Caucasians (9.5% vs. 40%). The median Hcy level in the
Chinese patients was 10.8 mmol/L, similar to that found in
the literature for healthy Asian patients and those with
VTE. It doesn’t therefore appear that HHcy is associated
with VTE in Asians or indeed with CVI in Chinese patients.
Figure 4 Box andwhisker plot indicating factor VIII activity for
UK Caucasian vs. HK Chinese patients.
Figure 5 Box and whisker plot indicating factor IX activity for
UK Caucasian vs. HK Chinese patients.
Figure 6 Box and whisker plot indicating factor XI activity for
UK Caucasian vs. HK Chinese patients.
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An elevated FVIII (defined as >150 IU/dl, or 150% activity) is
present in 10% of the general Caucasian population, and has
been found to be present in 20e25% of Caucasian VTE
patients.15,30,31 Risk of first VTE episode has been found to
increase by 10% with each 10% increase in FVIII activity,
even when values remain within the normal range.9,32 Mean
FVIII activity is higher in one study in Caucasians and
Japanese Americans compared with rural and urban Japa-
nese,33 and Chinese patients have been found to have
similar FVIII levels to Caucasians.18 Two studies have looked
at FVIII levels in Asian VTE patients. The first, a case series
of 50 consecutive Taiwanese Chinese patients with VTE
found no patients had a raised FVIII level.34 The second
study was a case series of 85 Thai patients with VTE and
without malignancy. 30.4% of the patients had a raised FVIII
level (>150 IU/dL).19 In the present study, high FVIII
activity levels were found in 14 and 19% of Chinese and
Caucasian patients respectively. There was no significant
difference in FVIII activity between Chinese and Caucasian
patients with CVI. FVIII activity does not appear in this
study to be related to CVI in Chinese patients.
Factor IX
Elevated FIX levels of >129% activity are found in 10% of the
general Caucasian population and are associated with an
almost 3-fold increase in the risk of VTE.16,35e37 No studies
were available that looked at the prevalence of raised FIX
in Asian patients, with or without VTE. In this study we
found raised FIX levels in over 30% of the Chinese patients
and over 50% of the Caucasian patients with CVI. We alsofound significantly higher FIX levels in the Caucasian
patients compared with the Chinese patients.
Factor XI
Elevated FXI levels of >121% activity are found in 10% of the
general Caucasian population and are associatedwith a 2-fold
Thrombophilia in Chinese Patients with CVI 265increase inVTE risk.17Angchaisuksirietal. founda raisedFXI in
26.8% of 85 Thai VTE patients without malignancy (defined as
>140 IU/dL) and concluded that high FXI is a risk factor for VTE
in Thais.19 In this study FXI activity was significantly higher in
the Caucasian patients when compared with the Chinese
patients.
The main weakness of this study is that we have no non-
venous control population for the Hong Kong patient group.
The reason for this is manpower and financial constraints.
However, there is no evidence from the literature that the
reference ranges of Hcy, and factors VIII, IX and XI are any
different in Chinese patients compared with Caucasian
populations. In the absence of different reference ranges it
is reasonable to use those that have been published, and
similar to those used in VTE studies in many Asian
populations.
In conclusion, Hong Kong Chinese patients with CVI do
not appear to have the high levels of homocysteine and
factors IX and XI that are seen in Caucasian patients with
CVI. As with the inherited thrombophilias, the pattern of
raised procoagulant factors in Chinese patients appears to
differ from Caucasians.Conflict of Interest/Funding
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